Download PDF
CC BY-NC-ND 4.0 · Am J Perinatol 2020; 37(04): 421-429
DOI: 10.1055/s-0039-1681014
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

Evan J. Anderson
1   Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia
,
John P. DeVincenzo
2   Departments of Pediatrics and Microbiology, Immunology, and Biochemistry, University of Tennessee School of Medicine, Memphis, Tennessee
,
Eric A. F. Simões
3   Section of Pediatric Infectious Disease, University of Colorado School of Medicine, Colorado School of Public Health, Children’s Hospital Colorado, Aurora, Colorado
,
Leonard R. Krilov
4   Division of Pediatric Infectious Disease, Children's Medical Center, NYU-Winthrop Hospital, Mineola, New York
,
Michael L. Forbes
5   Pediatric Critical Care Medicine, Akron Children's Hospital, Akron, Ohio
,
Pia S. Pannaraj
6   Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California, Keck School of Medicine, University of Southern California, Los Angeles, California
,
Claudia M. Espinosa
7   Pediatric Infectious Diseases, University of Louisville, Louisville, Kentucky
,
Robert C. Welliver
8   Pediatric Infectious Diseases, Children’s Hospital at OU Medical Center, Oklahoma City, Oklahoma
,
Leslie I. Wolkoff
9   Division of Neonatology, Connecticut Children's Medical Center, Hartford, Connecticut
,
Ram Yogev
10   Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Paul A. Checchia
11   Cardiac Intensive Care, Texas Children's Hospital, Houston, Texas
,
Joseph B. Domachowske
12   Pediatrics: Infectious Disease, SUNY Upstate Medical University, Syracuse, New York
,
Natasha Halasa
13   Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee
,
Scott J. McBride
14   United BioSource Corporation, Ann Arbor, Michigan
,
Veena R. Kumar
15   AstraZeneca, Gaithersburg, Maryland
,
Kimmie K. McLaurin
15   AstraZeneca, Gaithersburg, Maryland
,
Christopher P. Rizzo
15   AstraZeneca, Gaithersburg, Maryland
,
Christopher S. Ambrose
15   AstraZeneca, Gaithersburg, Maryland
› Author Affiliations Funding This study was sponsored by AstraZeneca. Editorial support was provided by The Lockwood Group, which was in accordance with Good Publication Practice (GPP3) guidelines and funded by AstraZeneca.
Further Information

Publication History

27 December 2018

22 January 2019

Publication Date:
16 April 2019 (online)

Also available at
   Permissions and Reprints
Zoom Image

Abstract

Objective The SENTINEL1 observational study characterized confirmed respiratory syncytial virus hospitalizations (RSVH) among U.S. preterm infants born at 29 to 35 weeks' gestational age (wGA) not receiving respiratory syncytial virus (RSV) immunoprophylaxis (IP) during the 2014 to 2015 and 2015 to 2016 RSV seasons.

Study Design All laboratory-confirmed RSVH at participating sites during the 2014 to 2015 and 2015 to 2016 RSV seasons (October 1–April 30) lasting ≥24 hours among preterm infants 29 to 35 wGA and aged <12 months who did not receive RSV IP within 35 days before onset of symptoms were identified and characterized.

Results Results were similar across the two seasons. Among infants with community-acquired RSVH (N = 1,378), 45% were admitted to the intensive care unit (ICU) and 19% required invasive mechanical ventilation (IMV). There were two deaths. Infants aged <6 months accounted for 78% of RSVH observed, 84% of ICU admissions, and 91% requiring IMV. Among infants who were discharged from their birth hospitalization during the RSV season, 82% of RSVH occurred within 60 days of birth hospitalization discharge.

Conclusion Among U.S. preterm infants 29 to 35 wGA not receiving RSV IP, RSVH are often severe with almost one-half requiring ICU admission and about one in five needing IMV.

Keywords

respiratory syncytial virus - infants - palivizumab - immunoprophylaxis - hospitalizations

Note

Portions of this work were presented at IDWeek 2016, New Orleans, LA, October 26–30, 2016; the Society of Critical Care Medicine's 46th Critical Care Congress, Honolulu, Hawaii, January 21–25, 2017; the Pediatric Academic Societies (PAS) 2017 Meeting, San Francisco, CA, May 6–9, 2017; IDWeek 2017, San Diego, CA, October 4–8, 2017; and the PAS 2018 Meeting, Toronto, ON, Canada, May 5–8, 2018.


Supplementary Material